Bharat Biotech's Covaxin efficacy results in Phase III trials: REVEALED!

Bharat Biotech's Covaxin has shown 77.8 percent efficacy after the Subject Expert Committee (SEC) under the drug regulator reviewed its Phase III trials data on Tuesday, according to sources, as per ANI.

The Hyderabad-based COVID vaccine manufacturing company had submitted data from the Phase III clinical trials of Covaxin to the Drugs Controller General of India (DCGI) over the weekend, according to a report by ANI.

See Zee Business Live TV Streaming Below:

The meeting happened before Bharat Biotech's pre-submission meeting on Wednesday with the World Health Organization (WHO), for the approval for their Covid vaccine 'Covaxin'.

Covaxin is one of the three vaccines which are currently being used in India. The phase III data of its vaccine has been questioned various times and this is what makes the data that ascertains the efficacy of the vaccine crucial.

The vaccine has been developed by the company in association with the Indian Council of Medical Research (ICMR).

Bharat Biotech had in May informed that an emergency use listing (EUL) application had been submitted to WHO, with regulatory approvals expected between July and September.